 BANNOCKBURN, Ill., Aug. 04, 2020 GLOBE NEWSWIRE -- Option Care Health, Inc. the Company or Option Care Health Nasdaq: OPCH, the nations largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2020. Given the merger between HC Group Holdings II, Inc. Option Care and BioScrip, Inc. BioScrip to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively. Further, as reported on February 3, 2020, the Company completed a reverse 1-for-4 stock split in the first quarter and, as a result, all per share data below is reported incorporating the effect of the reverse stock split as if it was effective for all periods reported.Second Quarter 2020 Financial Highlights Net revenue of 740.8 million, up 49 compared to 497.3 million in the second quarter of 2019 Gross profit of 166.3 million, or 22.4 of net revenue, up 64 compared to 101.4 million, or 20.4 of revenue, in the second quarter of 2019 Net loss of 7.7 million, or 0.04 per share, compared to net loss of 13.6 million, or 0.10 per share, in the second quarter of 2019 Run rate merger-related synergies at the end of the second quarter of more than 60 million Adjusted EBITDA of 54.6 million, up 131 compared to 23.7 million in the second quarter of 2019 Cash flow from operations of 35.0 million, up 163 compared to 13.3 million in the second quarter of 2019 Cash balances of 118.1 million at the end of the second quarter and no outstanding borrowings on the Companys 150.0 million revolverAdditionally, subsequent to the second quarter, the Company completed a sale of 18 million shares of common stock. Eight million shares were sold by HC Group Holdings, I, the primary shareholder of the Company. The Company also sold 10 million shares and received net proceeds of approximately 118 million, which will be used to retire a portion of its senior secured second lien PIK toggle floating rate notes due 2027. The impact of the sale of common stock will be reflected in the Companys third quarter results.John C. Rademacher, Chief Executive Officer, commented, I am very pleased with the second quarter financial results given the COVID-19 pandemic situation and the dynamic environment in which we are operating. Most importantly, I am proud of the dedication of the Option Care Health team who safely and effectively deliver on their promises every day ensuring patients receive the critical care they need.Update on the Impact of the COVID-19 PandemicAs anticipated, the COVID-19 pandemic had a significant impact on the Companys second quarter results. New patient referrals were negatively impacted across the portfolio of both acute and chronic therapies, with the largest impact on acute referrals that typically originate from hospital discharge events. Option Care Health incurred higher expenses related to both the procurement of personal protection equipment and medical supplies as well as with respect to its clinical labor.Offsetting the impact of the negative factors, the Company benefitted from the transfer of existing patients receiving infusion therapy in a hospital or other setting to receive therapy in the home or one of the Companys infusion suites. Comparable revenue growth for the quarter is estimated at approximately 7 when considering the impact of the merger and harmonization of accounting policies, with acute therapies declining in low single digits and chronic therapies growing in the low double digits.As previously disclosed, as part of the Coronavirus Aid, Relief, and Economics Security Act the Cares Act, the Company received approximately 11.7 million from the Public Health and Social Services Emergency Fund in the second quarter. The cash receipt was reflected in the second quarter results as a cash inflow from financing activities. Having considered the terms of the Cares Act and the second quarter results, the Company has decided to return the funds in their entirety in the third quarter. The outflow will be reflected as a cash outflow due to financing activities and there will be no impact on the Companys results from operations.Full Year 2020 GuidanceFor the full year, the Company expects to generate between 200 million and 210 million in Adjusted EBITDA and at least 50 million in free cash flow, defined by the Company as net change in ending cash balance compared to the cash balance at December 31, 2019.Conference CallThe conference call can be accessed by dialing 866 360-3136 for U.S. participants, or 602 563-8603 for international participants, and referencing conference ID 9790835; or via a live audio webcast that will be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.About Option Care HealthOption Care Health is the nations largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.Investor ContactsMike ShapiroBob East, Asher Dewhurst, Jordan Kohnstam Chief Financial OfficerWestwicke T: 312 940-2538T: 413 213-0500 Forward-Looking Statements - Safe Harbor This press release may contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: anticipate, intend, plan, believe, project, estimate, expect, may, should, will and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: i changes in laws and regulations applicable to our business model; ii changes in market conditions and receptivity to our services and offerings; iii results of litigation; iv the loss of one or more key payers; and v the spread and impact of the COVID-19 pandemic. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Note Regarding Use of Non-GAAP Financial MeasuresIn addition to reporting financial information in accordance with generally accepted accounting principles GAAP, the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Companys liquidity. In addition, the Companys definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain longlived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. 